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Aims: Determine prevalence of diabetes, and describe use of blood glucose lowering (BGL)
drugs and glycemic control in Norwegian nursing homes.
Methods: In this cross-sectional study we collected details of BGL drugs, capillary blood
glucose measurements (CBGM) in the last four weeks and HbA1c measurements in the last
12 months from the medical records of patients with diabetes, within a population of 742
long-term care patients from 19 randomly selected nursing homes in Western Norway.
Descriptive statistics were applied, and Pearson’s chi-squared (P  0.05) or non-overlapping
95% confidence intervals were interpreted as significant effects.
Results: 116 patients (16%) had diabetes, 100 of these gave informed consent and medical
data were available. BGL treatment was as follows: (1) insulin only (32%), (2) insulin and oral
antidiabetics (OADs) (15%), (3) OADs only (27%) and (4) no drugs (26%). Patients with
cognitive impairment were less likely to receive medical treatment (P = 0.04). CBGM and
HbA1c measurements were performed for 73% and 77% of patients, respectively. Mean
HbA1c was 7.3% (57 mmol/mol), 46% of patients had an HbA1c <7.0% (53 mmol/mol), and
CBGM consistent with risk of hypoglycemia was found for 60% of these patients.
Conclusions: Prevalence of diabetes and BGL treatment in Norwegian nursing homes is
comparable to other European countries. Although special care seems to be taken when
choosing treatment for patients with cognitive impairment, there are signs of overtreat-
ment in the population as a whole. The strict glycemic control unveiled may negatively
affect these frail patients’ quality of life and increase the risk of early death.
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The prevalence of diabetes is increasing worldwide, with the
highest rise in the population 60 years of age [1]. Diabetes in
the elderly is metabolically distinct from younger patients [2],
associated with an accelerated progression of both functional
and cognitive decline [3–5] and is a common cause of nursing
home admissions [6]. The reported prevalence of diabetes in
nursing homes varies from 11 to 36% around the world [7–13].
The majority of nursing home patients receive multiple
drug therapy and drug-related problems (DRPs) are common
[14]. Patients with diabetes have a higher burden of comorbid-
ities compared to patients without diabetes [10,15], further
complicating management of care. Hypoglycemic episodes
occur frequently, due to both an overly intensive drug regime
[7,11,16] and concurrent diseases [17,18]. Symptoms of
hypoglycemia in the elderly are often unspecific and less
marked compared to in younger patients [19,20] and may be
mistaken for symptoms of their cognitive or functional
impairment, or even stroke [20,21]. Hypoglycemia is associat-
ed with an increased risk of adverse clinical outcomes, such as
cardiovascular disease, dementia and death [22,23]. Lack of
guidelines for blood glucose monitoring [7,24], poor recogni-
tion of clinical symptoms that may call for unscheduled
measurements [9], and unclear limits of blood glucose
concentrations where the physician should be notified [24],
may further increase the risk and impact of hypoglycemia.
Guidelines for treatment have, until recently, been sparse
for frail, older patients. However, the new recommendations
concerning treatment of diabetes in this population have a
strong focus on reducing the risk of hypoglycemia in addition
to limiting hyperglycemia, both through reducing excessive
medical treatment and providing appropriate and sufficient
blood glucose monitoring. [25,26].
In Norway, a study from the Tromsø area that examined
subjects >69 years of age either receiving nursing care at home
or in an institution found a known diabetes prevalence of 20%
[27]. However, this study did not discriminate between
patients that received nursing care at home and patients
who were staying in an institution; neither did they include
patients with severe illness or dementia. Hence, diabetes
prevalence in Norwegian nursing homes has not been studied
exclusively, and the quality of diabetes care has not previously
been investigated for these patients. This study aims to
determine the prevalence of diabetes in Norwegian nursing
homes, and investigate the use of blood glucose lowering
drugs, frequency of capillary blood glucose measurements
(CBGM) and HbA1c measurements, and glycemic control in
this population. In addition, these aspects of diabetes care are
compared with the newer recommendations for diabetes
treatment and follow-up.
2. Subjects, materials and methods
2.1. Study design and participants
This cross-sectional study was performed within a population
of long-term care patients in nursing homes between Februaryand August 2012. Long-term care patients were defined as
patients admitted for a stay of 3 months. We drew a random
sample from all nursing homes (n = 180) within the geograph-
ical area of the Western Norway Regional Health Authority. A
total of 26 nursing homes were invited to participate and 20 of
these accepted, of which one withdrew after data collection
had begun. The 19 nursing homes were located in both rural
and urban areas, with a median long-term care population of
29 patients (range 8–136). Sixteen of the nursing homes were
owned by the municipality, whereas three were owned by
private foundations.
To ensure patients’ confidentiality nursing home staff
collected depersonalized data about year of birth, sex, and
which patients had a diagnosis of diabetes. Nursing home staff
also assessed diabetes patients’ capacity to give consent and
collected written, informed consent from patients. In cases
where patients themselves lacked capacity to consent, their
next of kin was asked to give consent on their behalf. The
study was approved by a regional committee for medical
research ethics (REK Vest).
The researcher (LMA) examined the nursing home medical
records of all consenting diabetes patients and registered any
blood glucose lowering drugs. They were defined as all drugs
within code A10 –‘‘Drugs used in diabetes’’ in the Anatomical
Therapeutic Chemical (ATC) classification system [28]. The
researcher also collected information on number of measure-
ments and concentrations of capillary blood glucose and
HbA1c within the last four weeks and twelve months,
respectively. In this population, we define hypoglycemia as
a blood glucose concentration <4.0 mmol/L and risk of
hypoglycemia as a fasting blood glucose concentration
<6.0 mmol/L [26]. Hyperglycemia is defined as a blood glucose
concentration >11.0 mmol/L [26].
2.2. Statistical analyses
Descriptive statistics for normally distributed continuous
variables are expressed as means with 95% confidence
intervals (CI). Non-overlapping confidence intervals are inter-
preted as significant effects. Continuous variables with a
skewed distribution are presented as median with range.
Categorical variables are presented as frequencies and
percentages. The 95% CI for the percentages were estimated
by the 2.5 and 97.5 percentiles from non-parametric boot-
strapped data (10,000 datasets were simulated for each CI).
Pearson’s chi-squared were used to test for significant effects.
P-values  0.05 were considered statistically significant. Sta-
tistical analyses were carried out using IBM SPSS Statistics 20.0
(IBM, Armonk, NY) and Microsoft Excel 2010 (Microsoft,
Redmond, WA, USA).
3. Results
3.1. Demographics
A total of 742 long-term care patients lived within the 19
participating nursing homes. Of these, 116 had a diagnosis of
diabetes (16%). Patients with diabetes did not differ from the
patients without diabetes in mean age (85.2 y [CI: 83.8, 86.6] vs.
Table 1 – Overview of drugs prescribed for regulating blood glucose (ATC-code: A10) divided into insulin injections and
oral antidiabetics (OADs) (n = 74).
ATC-code Substance Number of patients
with prescriptiona
Number of regular
prescriptions
Number of prnb
prescriptions
Insulins A10A A10AB05 Insulin aspart 31 3 31
A10AC01 Insulin isophane 25 25 0
A10AD05 Insulin aspart 9 9 1
A10AB01 Insulin isophane 7 0 7
A10AB04 Insulin lispro 3 1 2
A10AE05 Insulin detemir 3 3 0
A10AE04 Insulin glargine 1 1 0
A10AD04 Insulin lispro 1 1 0
Other antidiabetics A10B A10BA02 Metformin 27 27 0
A10BB12 Glimepiride 18 18 0
A10BB07 Glipizide 1 1 0
a As some patients are prescribed the drug both regular and prn, this number will not always add up to the sum of regular prescriptions + prn
prescriptions.
b Prn = pro re nata/as needed medication.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 5 ( 2 0 1 4 ) 1 0 2 – 1 0 910486.0 y [CI: 85.3, 86.7]) or in male to female ratio (0.49 vs. 0.37,
P = 0.22).
The study population consisted of 100 consenting patients
with diabetes, of which 52 were able to give informed consent
themselves. The 16 patients not consenting did not differ from
the consenting patients in age, in male to female ratio, or in
capacity to consent.
Seventy-five patients were registered with type 2 diabetes,
five with type 1 diabetes, and for twenty patients information
about type of diabetes was not given in the nursing home
medical records.
3.2. Drug regime
Nearly half of the patients (n = 47) were prescribed insulin, 32
of which were prescribed insulin only and 15 of which were
prescribed insulin and oral antidiabetics (OADs). Of the
patients with only a prn ( pro re nata–as needed) prescription
for insulin (n = 11), eight were in the insulin + OAD group.
Patients were prescribed a range of eleven different drugs for
lowering blood glucose (Table 1). Insulins most frequently
prescribed were insulin aspart (n = 44) and insulin isophane
(n = 32). Metformin (n = 27) and glimepiride (n = 18) were the
most commonly prescribed OADs.
A quarter of the patients (n = 26) received no blood glucose
lowering drugs (Table 2). These did not differ from other
patients in mean age, male to female ratio or type of diabetes
registered in their medical records. However, the percentage
of patients being prescribed blood glucose lowering drugs was
significantly higher for patients with capacity to consent
compared to patients without capacity to consent (82.7% vs.
64.6%, P = 0.04). The patients who received medical treatment
for their diabetes had an average of 1.8 [CI: 1.6, 1.9] prescribed
drugs for lowering blood glucose (range 1–3). Two of the
patients registered with type 1 diabetes were prescribed an
OAD (metformin) in addition to insulin.
3.3. Glycemic control
Seventy-three of 100 patients had one or more capillary blood
glucose measurements (CBGM) in the last four weeks. Mediannumber of CBGM was significantly higher for patients
receiving regular insulin injections compared to the other
treatment groups (P < 0.01) (Table 2). Thirteen patients had
daily CBGM, twelve of which received regular insulin injec-
tions and one patient who received sulfonylurea as a regular
medication.
Of the patients who had a record of CBGM in the last four
weeks, 60% had recorded one or more measurements of blood
glucose concentrations in the range of hypoglycemia
(<4.0 mmol/L) and/or risk of hypoglycemia (fasting blood
glucose <6.0 mmol/L). Fifteen percent of all recorded CBGM
were in the range of hypoglycemia or risk of hypoglycemia
(Table 3).
All patients who were prescribed insulin had at least one
recorded episode of a CBGM <6.0 mmol/L (fasting), and 62%
of these patients also had a record of CBGM >11.0 mmol/L.
For the ‘‘OAD group’’ the numbers were 48% and 11%,
respectively. None of the patients in the ‘‘No drugs group’’
had a record of CBGM <6.0 mmol/L, whilst 8% had a record
of CBGM >11.0 mmol/L. A record of CBGM <6.0 mmol/L was
significantly associated with higher mean HbA1c value (7.8%
[CI: 7.3, 8.3] (61 mmol/mol [CI: 56, 67]) vs. 6.5% [CI: 6.1, 6.9]
(48 mmol/mol [CI: 44, 52])). Patients with a record of CBGM
>11.0 mmol/L also had a significantly higher mean HbA1c
value compared to those with no recordings >11.0 mmol/L
(8.3% [CI: 7.7, 8.9] (67 mmol/mol [CI: 60, 74]) vs. 6.8% [CI: 6.4,
7.2] (51 mmol/mol [CI: 46, 55])). We did not find significant
differences in mean HbA1c value between patients with a
record of CBGM <4.0 mmol/L and patients with no record-
ings <4.0 mmol/L (8.0% [CI: 7.1, 9.0] (64 mmol/mol [CI: 53,
75]) vs. 7.2% [CI: 6.8, 7.6] (56 mmol/mol [CI: 51, 60])), or
between patients with a record of CBGM compared to those
with no recordings of CBGM the last four weeks (7.5% [CI:
7.0, 7.9] (58 mmol/mol [CI: 53, 62]) vs. 6.9% [CI: 6.1, 7.8]
(52 mmol/mol [CI: 43, 61])). Neither did we find an associa-
tion between number of CBGM and last recorded HbA1c
value (data not shown).
Twenty-three patients had no record of HbA1c measure-
ments during the last 12 months, 14 of which were prescribed
blood glucose lowering drugs. Forty patients had one recorded
HbA1c value, and in 37 patients the number of measurements
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ments (CBGM) the last four weeks from 73 patients.
Number
of
patients
Number
of CBGM
(n = 73) (n = 1006)
Blood glucose concentration n (%) n (%)
<4.0 mmol/La 10 (13.7) 31 (3.1)
<6.0 mmol/Lb 35 (47.9) 122 (12.1)
>11.0 mmol/La 34 (46.6) 367 (36.5)
a Random blood glucose concentration, not necessarily fasting.
b Fasting blood glucose concentration.
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from 4.7% (28 mmol/mol) to 12.4% (112 mmol/mol), with an
average of 7.3% [CI: 7.0, 7.7] (57 mmol/mol [CI: 53, 60]).
Distribution of HbA1c values by treatment is shown in
Fig. 1. Mean value of HbA1c was significantly higher when
prescribed insulin (8.0% [CI: 7.4, 8.6] (64 mmol/mol [CI: 58, 70]))
compared to patients prescribed only OADs (6.7% [CI: 6.4, 7.4]
(52 mmol/mol [CI: 46, 57])) or patients who did not receive
blood glucose lowering drugs (6.4% [CI: 5.8, 7.0] (46 mmol/mol
[CI: 40, 53])).
Seven patients neither received CBGM in the last four
weeks nor HbA1c measurements in the last 12 months. Four
of these patients were prescribed blood glucose lowering
drugs; three patients with a prescription for OADs only, and
one patient with a prescription for a regular OAD and insulin
prn.
Capacity to consent was not associated with a record of
CBGM (58% vs. 37%, P = 0.08). Neither did we find an
association between capacity to consent and having HbA1c
measured the last twelve months (53% vs. 48% [P = 0.81]),
nor last recorded value of HbA1c (7.4% [CI: 6.9, 7.9]
(57 mmol/mol [CI: 51, 63]) vs. 7.3% [CI: 6.7, 7.8] (56 mmol/
mol [CI: 50, 62])).0 
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Figure 1 – Distribution of last recorded HbA1c value (%,
mmol/mol) from 77 patients, sectioned into treatment
categories ‘‘Insulin’’, ‘‘OADs’’ and ‘‘No drugs’’.
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Our results show that 16% of long-term care patients in
Norwegian nursing homes have a known diagnosis of
diabetes. This is consistent with findings from other European
countries [7,11–13], and also comparable with the prevalence
previously reported for the elderly population receiving
nursing care either at home or in an institution in the Tromsø
area in Norway [27]. The majority of the patients in our study
(71%) receive blood glucose regulating drugs regularly, but
frequency and level of glycemic control vary greatly among the
patients.
Patients with diabetes were prescribed a variety of blood
glucose lowering drugs (Table 1), and choice of drugs, average
number of prescribed drugs, and proportion of patients in the
different treatment groups are comparable to what are
reported in other nursing home studies [7,11,29].
Metformin was the drug of choice for patients prescribed
OADs, whilst a basal regime with NPH-insulin was common in
insulin-treated patients (Table 1). This is consistent with
current recommendations for older people with diabetes,
although these also state that newer therapies may benefit
selected patients [26]. Insulin detemir and insulin glargine
have shown to be more beneficial than NPH-insulin for
patients at higher risk of hypoglycemia [30]. The same is true
for incretin mimetics in obese patients and DPP-4 inhibitors in
malnourished patients [31]. However, limited knowledge of
effect and safety of the newer therapies in the population aged
75 years, and higher costs may be an explanation for why
these drugs are seldom or never prescribed [30,31].
On average, the patients who received medical treatment
for their diabetes were prescribed more than one drug for
lowering their blood glucose, and almost half of them receive
regular insulin injections. The reason for this may be that
advanced age is associated with a decline in glucose tolerance
and b-cell function, leading to increased insulin resistance and
impaired insulin secretion [32]. Progressive loss of glycemic
control in type 2 diabetes with time, requiring several OADs
and ultimately insulin to achieve appropriate treatment, is
also well-known [33]. Although we do not have information
about duration of diabetes in these patients, it is reasonable to
believe that a number of them have had the disease for some
time. Jorde and Hagen reported the average duration of
diabetes to be 11.2  8.2 years [27]. They found that 46% of the
patients were treated with insulin compared to 47% of the
patients in our study. However, the majority of the Tromsø
patients received insulin together with OADs (35%), whilst in
our population patients mostly used insulin alone (32%). This
may be due to some demographic differences in our popula-
tions.
Low concentrations of fasting blood glucose (<6.0 mmol/L)
and/or hypoglycemic episodes (<4.0 mmol/L) were found for
60% of the patients with a record of CBGM (Table 3), which may
indicate overtreatment in these patients, but we do not know
if these patients experienced clinical symptoms of hypoglyce-
mia in these cases. However, as hypoglycemia is often
overlooked in these patients [20,21] and also associated with
an increased risk of cardiovascular events, dementia and
death [22,23], this number is worrying. Furthermore, numberof hypoglycemic episodes may be underestimated in our
study, as only one third of patients receiving regular insulin
have daily CBGM (Table 2). Frequent hypoglycemic episodes
among nursing home patients using insulin have also been
reported in other studies [9,11,34,35]. However, increased
CBGM may not be the solution for all patients to solve the
problem with hypoglycemia. Studies have shown that even
with regular CBGM in these patients, recommended glucose
targets were not met [36] and patients not at risk of
hypoglycemia experienced unnecessary measurements [35].
Furthermore, clinical symptoms that called for unscheduled
CBGM were overlooked [9], and the risk of hypoglycemic
episodes still was a considerable issue [9,35,36]. Shorter
periods, e.g. 24–72 h, with more frequent measurements, or
even continuous glucose monitoring, may give a better
understanding of the patient’s diurnal variation in blood
glucose than regular daily measurements.
Our study also showed that many patients who had
experienced low concentrations of blood glucose also had a
record of hyperglycemic episodes (>11.0 mmol/L). This glu-
cose variability suggests that management of nursing home
patients using insulin is challenging, and that hypoglycemic
episodes might be a problem even with higher levels of HbA1c.
It has been suggested that too much focus on treating a high
HbA1c, rather than individualizing the care for the patient is
the reason for this [21,37]. Guidelines recommend that HbA1c
should be taken at least every six months, regardless of
treatment and even if the patient’s glycemic control is stable
[25,38]. Over 60% of the patients in this study do not meet this
recommendation, possibly compromising initiation and fol-
low-up of treatment. Another worrying finding was that the
medical records of 26 patients receiving blood glucose
lowering drugs lacked information about level of glycemic
control, either in form of a CBGM record, an HbA1c value, or
both. Patients who receive medical treatment for their
diabetes should receive some sort of measurement to decide
their level of glycemic control, to make sure they receive the
appropriate treatment.
The newer guidelines have advocated less stringent HbA1c
goals (7.0–8.0% (53-64 mmol/mol)) for patients with advanced
age, one or several comorbidities and/or an increased risk of
hypoglycemia [25,26,38,39]. In our study, the levels of HbA1c
were not as low as reported in similar studies [11,12,34],
especially not for patients using insulin. Still, for 46% of the
patients with a record of HbA1c measurement the last 12
months, the last HbA1c value was below the recommended
limit of 7.0% (53 mmol/mol), whilst only a quarter of these
patients were within the recommended interval of 7.0–8.0%
(53–64 mmol/mol) (Fig. 1). Similar numbers were reported by
Jorde and Hagen [27]. Too tight glycemic control in aging
patients has been associated with adverse clinical outcomes
[40,41]. The Action to Control Cardiovascular Risk in Diabetes
(ACCORD) study reported significantly higher frequency of
hypoglycemia requiring assistance, and also a significantly
higher risk of death in patients receiving an intensive drug
regime (mean HbA1c at study end 6.4% (46 mmol/mol))
compared with patients receiving standard therapy (mean
HbA1c at study end 7.5% (58 mmol/mol)) [40]. Currie et al.
showed that HbA1c values in the lower range (<7.5%
(58 mmol/mol)) were significantly associated with an
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 5 ( 2 0 1 4 ) 1 0 2 – 1 0 9 107increased risk of mortality in patients using insulin, com-
pared to HbA1c values between 7.5% and 9.0% (58 and
75 mmol/mol) [41]. Furthermore, a more intensive glycemic
control requires more drugs or more frequent dosing of drugs,
and it also increases the risk of drug–drug or drug–disease
interactions and adverse drug events. Norwegian nursing
homes should to a greater extent adjust their HbA1c
treatment goals according to the new recommendations, as
many of the patients in our study had an HbA1c in the lower
range. The high number of patients with a record of low blood
glucose concentrations in our study further demonstrates the
importance of less stringent HbA1c treatment goals for these
patients, especially if they have a limited life expectancy and
several comorbidities.
An interesting finding in our study was that lack of capacity
to consent was significantly associated with not receiving
blood glucose lowering drugs. However, we did not find any
significant differences in receiving CBGM or HbA1c measure-
ments, or average HbA1c results based on decisional capacity.
A lack of decisional capacity is associated with impaired
cognitive function [42], and differences in diabetes manage-
ment due to impaired cognitive function have been reported
[43–45]. However, in contrast to our findings, McNabney et al.
report no difference in choice of oral agents between nursing
home patients with different levels of both functional and
cognitive impairment, and do find lower intensity of both
CBGM and HbA1c measurements [45]. Less frequent HbA1c
measurements for patients with dementia is also reported by
Quinn et al. and Thorpe et al. [43,44]. None of these studies
investigated differences in HbA1c results. While it is difficult to
point out reasons for these differences, part of the explanation
may be that a recent patient safety campaign in Norway has
focused on minimizing drug treatment in nursing home
patients, especially those with dementia [46]. Restrictions in
both drug therapy and monitoring practices may be beneficial
for patients with cognitive impairment. A recent study
reported worsened cognitive performance for patients using
metformin compared to those who were not [47], suggesting
that excessive drug treatment may do more harm than good.
According to our study, glycemic control of patients without
capacity to consent is as good as that of patients with capacity
to consent, even if they do receive less blood glucose lowering
drugs.
To our knowledge, this is the first descriptive study of
Norwegian nursing home patients with diabetes residing in
long-term care. We included different sized nursing homes
from three counties, located in both urban and rural areas.
This should make the results representative for the general
nursing home population in Norway. Our results also support
findings in similar studies from other European countries,
strengthening the knowledge basis for this population. As we
did not collect information about length of stay, our results of
the HbA1c measurements may be biased. Patients with a stay
less than 12 months may have received HbA1c measurements
that are not documented in the nursing home medical records.
Transfer of medical information between care levels have
been shown to sometimes be inadequate [48], which also
raises concern about the validity of the treatment foundation.
However, three out of four patients did have at least one record
of an HbA1c result the last 12 months, giving a reasonableestimate of glycemic control in this population. We did not
collect information about duration of diabetes, nutrition/diet,
weight/BMI, other diagnoses, drugs or laboratory values from
these patients, and hence could not investigate how these
aspects may have influenced blood glucose lowering treat-
ment and glycemic control. A more comprehensive diagnosis
and medication review for these patients should be included
in future studies, to gain a better understanding of the medical
challenges and needs for these patients. Future research
should also include a more thorough investigation of glycemic
control in these patients, as well as CBGM and HbA1c
measurement practices in nursing homes, as these aspects
of care are essential for initiation and follow-up of treatment.
In conclusion, the prevalence and blood glucose lowering
treatment of diabetes in Norwegian nursing homes is
comparable to other European countries. Special care seems
to be taken when choosing blood glucose lowering treatment
for patients with cognitive impairment. However, the high
number of insulin treated patients, together with several
recordings of low blood glucose concentrations and low HbA1c
values suggest that some patients are subject to overtreat-
ment. This may result in lower quality of life and increase the
risk of early death. Newer guidelines recommend less
stringent HbA1c limits for older patients [25,26,38,39] and
Norwegian nursing homes should adjust their treatment
targets for patients with diabetes accordingly. Individual care
planning should also be applied, especially for patients with
high variability in glucose concentrations.
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